A randomized, open-label phase II study of single-agent vintafolide versus vintafolide plus docetaxel versus docetaxel alone in second-line NSCLC patients with all target lesions expressing folate-receptor (TARGET).
Martin J. Edelman
Consultant or Advisory Role - Endocyte
Research Funding - Endocyte
Hong Ma
Employment or Leadership Position - Endocyte
Stock Ownership - Endocyte
Wendy Perez
Employment or Leadership Position - Endocyte
Stock Ownership - Endocyte
Alex A. Adjei
No relevant relationships to disclose
Nasser Hanna
Research Funding - Endocyte